Fig. 7: Gemcitabine-induced G2/M arrest and apoptosis in H1299 TP53-null cells. | Cell Death Discovery

Fig. 7: Gemcitabine-induced G2/M arrest and apoptosis in H1299 TP53-null cells.

From: Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer

Fig. 7

This figure illustrates the impact of gemcitabine treatment on cell cycle progression and apoptosis in H1299 TP53-Null cells. Cell cycle analysis by flow cytometry is performed on both H1299 TP53 wild-type (WT) (A) and TP53-Null cells (B) after 48 h and 72 h of gemcitabine treatment. C, D The graphs display the population distribution among different cell cycle phases in H1299 TP53-WT cells and TP53-Null cells under gemcitabine treatment for 48 and 72 h, respectively. The data are presented as mean ± standard deviation (SD). The figure demonstrates that gemcitabine treatment induces G2/M arrest and apoptosis in H1299 TP53-Null cells, as reflected in the altered cell cycle distribution and the population of cells in various phases. The observed effects of gemcitabine treatment are compared between H1299 TP53-WT and TP53-Null cells. Statistically significant differences are indicated by asterisks in the graphs.

Back to article page